期刊
CELLS
卷 8, 期 5, 页码 -出版社
MDPI
DOI: 10.3390/cells8050394
关键词
Hedgehog; Smoothened; GLI factors; clinical trials; vismodegib; sonidegib
类别
资金
- National Institutes of Health from the NCI [CA136526]
- National Institutes of Health through the Mayo Clinic Pancreatic Specialized Program of Research Excellence [P50 CA102701]
- National Institutes of Health through the Mayo Clinic Center for Cell Signaling in Gastroenterology [P30 DK84567]
The Hedgehog/GLI signaling pathway plays an important role in normal embryonic tissue development and has been implicated in the pathogenesis of various human cancers. In this review article, we summarize pre-clinical evidence supporting the suitability of targeting this signaling pathway in cancers. We review agents blocking both the ligand-dependent and ligand-independent cascades, and discuss the clinical evidence, which has led to the FDA approval of Hedgehog receptor Smoothened inhibitors, vismodegib, and sonidegib, in different malignancies. Finally, we provide an overview of published and ongoing clinical trial data on single agent or combination therapeutic strategies, targeting Hedgehog/GLI signaling pathway, in both advanced solid tumors and hematologic malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据